SCHEMBL16833045

SCHEMBL16833045

Cc1ccc2nc(C(N)=O)cc(C(=O)O)c2c1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
KDM4E B2RXH2 4/20 0.58
HSD17B10 Q99714 3/20 0.58
GRM2 Q14416 10/20 0.54
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
HPGD P15428 2/20 0.49
POLB P06746 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
DHODH Q02127 1/20 0.48
CYP1A2 P05177 1/20 0.46
TSHR P16473 1/20 0.46
NQO2 P16083 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806000 0.89 ALDH1A1 (0.63) ALDH1A1KDM4EHSD17B10MEN1KMT2A
SCHEMBL16833596 0.85 NQO2 (0.61) ALDH1A1KDM4EGRM2KMT2ASMN1; SMN2
SCHEMBL30049727 0.83 ALDH1A1 (0.67) ALDH1A1KDM4EHSD17B10MEN1KMT2A
SCHEMBL15566039 0.83 ALDH1A1 (0.67) ALDH1A1KDM4EHSD17B10MEN1KMT2A
SCHEMBL28100426 0.82 KDM4E (0.56) ALDH1A1KDM4EHSD17B10MEN1KMT2A
SCHEMBL16832575 0.81 RXFP1 (0.56) ALDH1A1KDM4EHSD17B10GRM2MEN1
SCHEMBL16832263 0.81 PTGES (0.60) ALDH1A1KDM4EHSD17B10GRM2KMT2A
SCHEMBL16832220 0.81 DHODH (0.56) ALDH1A1GRM2MEN1KMT2ADHODH
SCHEMBL9724191 0.81 LMNA (0.58) GRM2SMN1; SMN2LMNA
SCHEMBL16832417 0.81 KDM4E (0.72) ALDH1A1KDM4EHSD17B10GRM2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-02-09 US disclosed
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-02-09 US disclosed
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-02-09 US disclosed
EP-3083598-A1 GLUCOSE TRANSPORT INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2016-10-26 EP disclosed
CN-106029647-A Glucose transport inhibitors 拜耳制药股份公司 2016-10-12 CN disclosed
WO-2015091428-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 WO disclosed
WO-2015091428-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS SLC2A1, SLC2A2, SLC2A4 ALDH1A1 432/4885KDM4E 3458/4885HSD17B10 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.